• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Infect . Oseltamivir is protective for in-patient mortality in PCR confirmed influenza B and influenza A(H3N2) infections in an historic cohort o

tetano

Editor, Senior Moderator
J Infect


. 2023 Jan 13;S0163-4453(23)00003-8.
doi: 10.1016/j.jinf.2023.01.004. Online ahead of print.
Oseltamivir is protective for in-patient mortality in PCR confirmed influenza B and influenza A(H3N2) infections in an historic cohort of 1,064 patients hospitalised during the 2016-17 and 2017-18 influenza seasons


Mark Reacher[SUP] 1 [/SUP], Ben Warne[SUP] 2 [/SUP], Neville Q Verlander[SUP] 3 [/SUP], Ashley Popay[SUP] 4 [/SUP], Lucy Reeve[SUP] 5 [/SUP], Nicholas K Jones[SUP] 6 [/SUP], Kyriaki Ranellou[SUP] 7 [/SUP], Nyaradzai Sithole[SUP] 8 [/SUP], Rory Carpenter[SUP] 9 [/SUP], Angharad Everden[SUP] 10 [/SUP], Elizabeth Jarman[SUP] 11 [/SUP], Ali Khalid[SUP] 12 [/SUP], Kyle Lam[SUP] 13 [/SUP], Chloe Myers[SUP] 14 [/SUP], Shuhui Ren[SUP] 15 [/SUP], Kathryn J Rolfe[SUP] 16 [/SUP], Tommy Sutton[SUP] 17 [/SUP], Silvana Christou[SUP] 18 [/SUP], Callum Wright[SUP] 19 [/SUP], Saher Choudhry[SUP] 20 [/SUP], Maria Zambon[SUP] 21 [/SUP], Clare Sander[SUP] 22 [/SUP], Hongyi Zhang[SUP] 23 [/SUP], Hamid Jalal[SUP] 24 [/SUP]



Affiliations

Abstract

Standard course oseltamivir 75mg two times daily for five days was associated with an 82% reduction of odds of in-patient death (OR 0.18 (0.07,0.51)) compared to no oseltamivir treatment (OR 1.0 Reference) in a final multivariable logistic regression model of a retrospective cohort of PCR confirmed influenza B and influenza A (H3N2) infected patients admitted to a large UK teaching hospital in influenza seasons 2016-17 and 2017-18. No difference of protective odds for standard course oseltamivir was observed between influenza B and influenza A (H3N2) nor between influenza seasons. These observations strongly support clinical guidelines for molecular testing for respiratory viruses on admission to hospital and prompt treatment of confirmed seasonal influenza B and A with oseltamivir 75mg twice daily for five days.

Keywords: Historic Cohort study; PCR; influenza A (H3N2) in-patient mortality; influenza B; logistic regression; multiplex PCR; multivariable logistic regression.
 
Back
Top Bottom